Výsledky vyhledávání - "Julia Hemmerling"

Human Epidermal Langerhans Cells Replenish Skin Xenografts and Are Depleted by Alloreactive T Cells In Vivo

Autor: Ralf G. Meyer, Rudolf E. Schopf, Matthias Theobald, Joanna Wegner-Kops, Maya C. André, Wolfgang Herr, Diana Wolff, Julia Hemmerling, Udo F. Hartwig, Esther von Stebut, Eva Wagner

Publikováno v: The Journal of Immunology. 187:1142-1149

Epidermal Langerhans cells (LC) are potent APCs surveying the skin. They are crucial regulators of T cell activation in the context of inflammatory skin disease and graft-versus-host disease (GVHD). In contrast to other dendritic cell subtypes, murin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbf29ed30e128f1de2319876a9737498
https://doi.org/10.4049/jimmunol.1001491

Zobrazit plný text záznamu

Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation

Autor: Eva Wagner, Eddy Roosnek, Timo Schmitt, Klaus Bender, Ralf G. Meyer, Christoph Huber, Abdo Konur, Udo F. Hartwig, Karin Kolbe, Daniela Wehler, Julia Hemmerling, Wolfgang Herr

Publikováno v: Bone Marrow Transplantation, Vol. 45, No 4 (2010) pp. 668-674

Donor lymphocyte infusions (DLI) are used to resolve mixed T-cell chimerism (TCC) after allo-SCT despite a substantial risk of GVHD. We analyzed the impact of prophylactic CD8-depleted (CD8(depl)) DLI in 20 recipients of anti-CD52 alemtuzumab in vivo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5d5b9b595c4b26ea54329058e72dffd
https://pubmed.ncbi.nlm.nih.gov/19684624

Zobrazit plný text záznamu

Long-Term Persistence of Functionally Altered GPI-Anchor Negative T-Cell Subsets After Alemtuzumab-Based T-Cell Depleted Hematopoietic Stem Cell Transplantation

Autor: Julia Hemmerling, Eva Wagner, Diana Wolff, Timo Schmitt, Ralf G. Meyer, Christoph Huber, Aline N Lay, Wolfgang Herr

Publikováno v: Blood. 114:2438-2438

Abstract 2438 Poster Board II-415 The anti CD52 antibody alemtuzumab is frequently used for in vivo T cell depletion (TCD) in the context of allogeneic hematopoietic stem cell transplantation (HSCT). We have recently demonstrated the persistence of C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea04e9422a9f6a1a6fd64ed6aff86dbc
https://doi.org/10.1182/blood.v114.22.2438.2438

Zobrazit plný text záznamu

Evaluation Of Alloimmune Responses In Humanized NOD/SCID/IL2rgnull Mice Following Human CD34+ Stem Cell Transplantation

Autor: Ralf G. Meyer, Julia Hemmerling, J. Hoffmann, Udo F. Hartwig, Christoph Huber, M.C. Andre, Rupert Handgretinger, Wolfgang Herr

Publikováno v: Biology of Blood and Marrow Transplantation. 15:130

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeb4dcd37521ac458b010920bc497c02
https://doi.org/10.1016/j.bbmt.2008.12.397

Zobrazit plný text záznamu

Reconstitution of CD52-Negative CD4 T Cells after Alemtuzumab-Based T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Autor: Ralf G. Meyer, Abdo Konur, Julia Hemmerling, Timo Schmitt, Klaus Bender, Wolfgang Herr, Christoph Huber, Eva Wagner, Aline N Lay, Sina Wenzel

Publikováno v: Blood. 112:1182-1182

The human CD52 molecule is the target of the monoclonal antibody Alemtuzumab, which is used for treating patients with chemo-refractory chronic lymphocytic leukemia as well as for T cell depletion (TCD) in the context of allogeneic hematopoietic stem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::272cb96179cc0e041b414257885321ad
https://doi.org/10.1182/blood.v112.11.1182.1182

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání